Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Improving wound healing function and storage stability of stem cell-derived extracellular vesicles via lyophilized hyaluronic acid formulation.

Bui VD., Duong VH., You DG., Jang WH., Lee J., An JY.

Animal Study on Chronic Wound, Chronic Inflammation, published in J Nanobiotechnology (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Nanobiotechnology (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41723471
PMCID
PMC13032532
DOI
10.1186/s12951-026-04201-y

Abstract (original English)

Although therapeutic extracellular vesicles (EVs) hold great promise for clinical applications, their limited targeting efficiency and poor storage stability remain critical barriers to clinical translation. Here, we present a lyophilized hyaluronic acid (HA)-coated formulation of EVs derived from human adipose stem cells, engineered to enhance both therapeutic efficacy and long-term preservation. This formulation leverages the natural affinity between HA and the CD44 proteins expressed on the EV membranes, forming stable HA-EV complexes that remain intact following lyophilization and rehydration. These HA-EVs exhibited superior targeting of CD44-expressing cells, including pro-inflammatory macrophages and senescent dermal fibroblasts, thereby effectively suppressing inflammatory responses and restoring fibroblast function in a wound-healing mouse model. Notably, HA-EVs significantly accelerate wound healing by promoting collagen synthesis within the dermal layer, outperforming bare EVs. Furthermore, HA served as an effective cryoprotectant, preserving the physicochemical and biological integrity of EVs for at least six months at 4 ℃. Taken together, our results establish lyophilized HA-EVs as a robust and clinically translatable platform that integrates cell-specific targeting with long-term storage stability for regenerative medicine applications.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Hyaluronic AcidAnimalsHumansWound HealingFreeze DryingMiceExtracellular VesiclesHyaluronan ReceptorsStem CellsFibroblasts

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research